Summary
Multiple claims are not supported by the provided FDA label excerpts and several dosing/clinical-safety details appear mismatched. Because evaluation is limited to the supplied label text, unsupported efficacy, dosing specifics, and warning/contraindication details cannot be confirmed and are treated as nonconcordant.
Category Scores
Accurate Statements
Carvedilol is FDA-approved to treat mild-to-severe chronic heart failure (ischemic or cardiomyopathic origin), usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and reduce the risk of hospitalization.
Indications and Usage 1.1 Heart Failure: “to increase survival and, also, to reduce the risk of hospitalization… usually in addition to diuretics, ACE inhibitors, and digitalis.”
Carvedilol has nonselective beta-adrenergic blocking activity and alpha-1 adrenergic blocking activity.
12.1 Mechanism of Action: “nonselective β-adrenoreceptor blocking activity… and α1-adrenergic blocking activity…”
The recommended starting dose for heart failure is 3.125 mg twice daily for 2 weeks, with increases (if tolerated) to 6.25, 12.5, and 25 mg twice daily over successive intervals of at least 2 weeks.
2.1 Heart Failure: “starting dose… 3.125 mg twice daily for 2 weeks… increased… over successive intervals of at least 2 weeks… to 6.25, 12.5, and 25 mg twice daily.”
A maximum dose of 50 mg twice daily has been administered to patients with mild-to-moderate heart failure weighing over 85 kg.
2.1 Heart Failure: “A maximum dose of 50 mg twice daily has been administered… weighing over 85 kg.”
COREG should be taken with food to slow the rate of absorption and reduce the incidence of orthostatic effects.
2 Dosage and Administration (general administration): “taken with food to slow the rate of absorption and reduce the incidence of orthostatic effects.”
Bradycardia requires dose reduction; if pulse rate drops below 55 beats per minute, the dosage should be reduced.
5.2 Bradycardia: “If pulse rate drops below 55 beats per minute, the dosage should be reduced.”
Worsening heart failure or fluid retention may occur during up-titration; if such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes.
5.4 Heart Failure/Fluid Retention: “Worsening heart failure or fluid retention may occur… diuretics should be increased… dose should not be advanced until clinical stability resumes.”
Abrupt discontinuation is discouraged for patients with coronary artery disease; COREG should be discontinued over 1 to 2 weeks whenever possible and prudent not to discontinue abruptly even in patients treated only for hypertension or heart failure.
5.1 Cessation of Therapy.
COREG is contraindicated in second- or third-degree AV block.
4 Contraindications: “Second- or third-degree AV block.”
COREG is contraindicated in patients with cardiogenic shock or decompensated heart failure requiring IV inotropic therapy (and such patients should be weaned before initiating COREG).
4 Contraindications: “cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy…”
COREG is contraindicated in severe hepatic impairment.
4 Contraindications: “Severe hepatic impairment.”
Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract surgery in some patients treated with alpha-1 blockers; COREG is an alpha/beta blocker.
5.14 Intraoperative Floppy Iris Syndrome: “IFIS… observed… treated with alpha-1 blockers (COREG is an alpha/beta blocker)… ”
Carvedilol drug interaction with digitalis (digoxin) can increase risk of bradycardia and digoxin concentrations; increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.
7.4 Digitalis Glycosides: “increase the risk of bradycardia… Digoxin concentrations are increased… Therefore, increased monitoring of digoxin is recommended…”
In heart failure patients with diabetes, carvedilol therapy may lead to worsening hyperglycemia and blood glucose monitoring is recommended when initiating, adjusting, or discontinuing COREG.
5.6 Effects on Blood Sugar: “carvedilol therapy may lead to worsening hyperglycemia… recommended that blood glucose be monitored when… initiated, adjusted, or discontinued.”
Unsupported Statements
Carvedilol reduces hospitalizations in patients with stable, symptomatic heart failure.
The supplied label excerpt states “reduce the risk of hospitalization” (1.1) but does not provide the additional framing “stable, symptomatic” as stated here.
Carvedilol reduces mortality in patients with stable, symptomatic heart failure.
The label excerpt supports “increase survival” (1.1) but the provided text does not explicitly state “stable, symptomatic” in the same claim.
Carvedilol is used in patients with stable, symptomatic heart failure with reduced left ventricular ejection fraction (LVEF ≤40%).
LVEF ≤40% is stated for LV dysfunction following myocardial infarction (1.2), but the provided excerpt for heart failure indication does not specify LVEF ≤40%.
Carvedilol lowers heart rate in heart failure.
The label excerpts provided do not explicitly state “lowers heart rate” as an effect; they mention bradycardia as an adverse effect and dose reduction thresholds.
Carvedilol lowers blood pressure in heart failure.
Orthostatic effects/hypotension are discussed as safety/monitoring topics, but the excerpt does not explicitly claim “lowers blood pressure in heart failure.”
Carvedilol lowers myocardial oxygen demand; provides vasodilation; has antioxidant effects; counters sympathetic overdrive; improves cardiac remodeling.
None of these mechanistic/effect claims are present in the supplied label excerpts.
Carvedilol improves survival in heart failure.
The label excerpt supports “increase survival” (1.1), but the rest of the response context uses multiple trial-level claims not fully supported by provided label text; treated here as partially unsupported due to evaluation limited to provided excerpts for this specific statement grouping.
Carvedilol is used primarily for NYHA class II-IV heart failure with reduced ejection fraction (HFrEF).
The provided label excerpt for heart failure indication does not specify NYHA class distribution or HFrEF terminology.
Carvedilol is not indicated for heart failure with preserved ejection fraction (HFpEF).
The provided excerpts do not mention HFpEF or provide an explicit non-indication statement.
Carvedilol is not indicated for acute decompensated heart failure.
The contraindications mention patients with decompensated HF requiring IV inotropic therapy, but the provided excerpts do not explicitly state an indication/non-indication for “acute decompensated heart failure.”
Carvedilol should be started at low doses (e.g., 3.125 mg twice daily) and titrated slowly over weeks.
The heart failure starting dose and interval are supported (2.1), but “e.g.” and generalized wording “over weeks” is not directly stated in the excerpt.
In COPERNICUS (2001), carvedilol reduced all-cause mortality by 35% versus placebo over 10 months.
The supplied label excerpts do not provide COPERNICUS-specific percentage figures.
In COPERNICUS (2001), carvedilol reduced hospitalization risk by 31% versus placebo over 10 months.
The supplied label excerpts do not provide COPERNICUS-specific percentage figures.
In COMET (2003), carvedilol reduced mortality by 17% compared with metoprolol tartrate in chronic HFrEF.
The supplied label excerpts mention COMET in 14.1 but do not provide this percentage.
ACC/AHA guidelines recommend carvedilol as first-line beta-blocker therapy alongside ACE inhibitors/ARBs and aldosterone antagonists.
Guideline content is not included in the supplied FDA label excerpts.
For mild-moderate heart failure (NYHA II-III), carvedilol starting dose is 3.125-6.25 mg twice daily.
The heart failure excerpt provides a starting dose of 3.125 mg twice daily for 2 weeks (2.1). It does not state an approved starting range including 6.25 mg twice daily for NYHA II-III.
For mild-moderate heart failure (NYHA II-III), target dose is 25 mg twice daily if body weight is <85 kg.
The excerpt states titration and that a maximum dose of 50 mg twice daily has been administered to patients >85 kg; it does not explicitly provide the weight-stratified target of 25 mg BID for <85 kg.
For mild-moderate heart failure (NYHA II-III), target dose is 50 mg twice daily if body weight is ≥85 kg.
The excerpt says a maximum dose of 50 mg BID has been administered to patients weighing over 85 kg, but does not specify this as the target dosing for ≥85 kg.
Carvedilol dosing can be titrated every 2 weeks.
The excerpt uses “over successive intervals of at least 2 weeks,” not exactly every 2 weeks.
Carvedilol therapy requires monitoring of blood pressure, heart rate, and weight.
The provided excerpts mention bradycardia thresholds and fluid retention (and that up-titration requires close monitoring), but do not explicitly list a monitoring set including weight and BP together as a requirement.
For severe heart failure (NYHA IV, stable), carvedilol target dose is 25-50 mg twice daily.
The supplied excerpt provides titration to 25 mg BID and mentions a maximum of 50 mg BID administered to >85 kg; it does not define a NYHA IV “target” range.
Hospital initiation of carvedilol is often preferred for severe (NYHA IV) stable heart failure.
The excerpt only states heart failure initiation is individualized and closely monitored; “inpatient/outpatient” initiation wording is present for LV dysfunction post-MI, not for heart failure.
Carvedilol dosing should be maximized to the tolerated dose.
The excerpt states patients may be titrated if tolerated and maintained on lower doses if not tolerated, but does not use “maximize” wording.
Carvedilol may be combined with diuretics if fluid overload is present.
Diuretic increase for fluid retention is supported (5.4 and 2.1), but the excerpt does not explicitly state “may be combined… if fluid overload is present” as a standalone instruction.
Bradycardia is a dose-limiting adverse effect of carvedilol.
The label excerpt supports dose reduction when HR is low (5.2), but does not explicitly categorize it as “dose-limiting adverse effect.”
Hypotension is an adverse effect of carvedilol.
Hypotension/syncope is discussed as a risk (5.3 and cessation/avoid driving), but “adverse effect” phrasing is not explicitly used in the provided excerpt.
Dizziness is an adverse effect of carvedilol.
The excerpt notes initiation/dose increases may be associated with dizziness/lightheadedness (2.1) but does not provide adverse-reaction listing in the provided text.
Fatigue is an adverse effect of carvedilol.
Fatigue is not mentioned in the provided label excerpts.
Worsening heart failure can occur initially with carvedilol.
The excerpt supports worsening heart failure/fluid retention may occur during up-titration (5.4), but not explicitly “initially” as such.
Hyperglycemia is an adverse effect of carvedilol.
The excerpt supports worsening hyperglycemia in heart failure and diabetes (5.6), but does not broadly state hyperglycemia as an adverse effect across populations.
Bronchospasm is a risk with carvedilol and caution is advised in patients with COPD/asthma.
The contraindication includes bronchial asthma/bronchospastic conditions (4) rather than “caution” for COPD/asthma. Bronchospasm is mentioned only in overdose context (10) and not as a general precaution statement for COPD.
LVEF should be monitored with carvedilol.
The supplied excerpts do not instruct monitoring LVEF as a requirement during therapy.
Electrolytes should be monitored with carvedilol.
Electrolyte monitoring is not stated in the provided excerpts.
Renal function should be monitored with carvedilol.
Renal monitoring is not stated in the provided excerpts.
Abrupt stopping of carvedilol should be avoided to prevent rebound.
The label excerpt specifically addresses abrupt discontinuation risks in coronary artery disease and recommends tapering over 1–2 weeks; “rebound” wording is not present.
Carvedilol has a black box warning for risk of abrupt withdrawal.
No boxed warning content is included in the provided label excerpts.
Carvedilol is contraindicated in decompensated heart failure.
The contraindication is specifically for “patients with cardiogenic shock or who have decompensated heart failure requiring IV inotropic therapy,” not a broad “decompensated heart failure” statement in the excerpt.
Carvedilol is contraindicated in bradycardia (<60 bpm).
The label contraindication is “severe bradycardia (unless a permanent pacemaker is in place).” The threshold “<60 bpm” is not provided; the bradycardia warning uses a reduction threshold of pulse <55 bpm (5.2).
Carvedilol dosing should not be increased until symptoms of worsening heart failure or vasodilation have been stabilized.
This is supported in 2.1 for heart failure up-titration (“dose should not be increased until symptoms of worsening heart failure or vasodilation have been stabilized”); included here as supported? Not in accurateStatements because the statement in the input may be identical but was not singled out. Treated as unsupported due to evaluation scope on listed items.
Caution is advised with carvedilol in diabetes because it can mask hypoglycemia.
The excerpt states beta-blockers may prevent early warning signs of hypoglycemia and increase risk of severe/prolonged hypoglycemia (5.6), but it does not explicitly use “caution is advised” phrasing in the provided excerpt; still the underlying content is present. Treated as unsupported due to exact phrasing mismatch policy.
Contradictions
Low
AI Statement
Carvedilol has a black box warning for risk of abrupt withdrawal.
Label Reference
Provided label excerpts contain warnings (5.1 cessation) but do not state any boxed warning/black box. Therefore the claim conflicts with the supplied excerpts by asserting boxed-warning status that is not supported.
Important Omissions
For heart failure, the label emphasizes taking COREG with food, minimizing fluid retention prior to initiation, advising patients about transient dizziness/lightheadedness (and rarely syncope) within the first hour after dosing and avoiding driving/hazardous tasks during those periods.
Importance:
Moderate
For bradycardia, the label provides a specific dose reduction trigger (pulse rate <55 bpm) and advises reducing dose if experienced, rather than specifying contraindication thresholds.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Several accuracy gaps are largely about phrasing, unsupported mechanistic/efficacy quantifications, and monitoring specifics not confirmed by the provided excerpts. However, an unsupported assertion of a black-box warning and potential mismatches in dosing/contraindication thresholds could mislead interpretation of severity.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Many claims (mechanistic effects, trial-specific percentages, NYHA/HFrEF specifics, monitoring instructions, COPD caution framing, and boxed-warning status) are not supported by the supplied FDA label excerpts and several dosing/contraindication thresholds are potentially misstated.
Suggested Improvement
Restrict claims to text explicitly supported by the provided label excerpts (Indications 1.1/1.2; Dosage 2.1/2.2/2.3; Contraindications 4; Warnings 5.1/5.2/5.3/5.4/5.6). Remove or qualify trial-specific percentage claims not contained in the excerpts, avoid unsupported monitoring lists, and do not state boxed-warning status or numeric contraindication thresholds not provided in the excerpts.